Whitepapers

Workflows to identify cancer biomarkers

G-CON’s floorlessPOD is a free-standing structure that provides direct integration with the host facility floor, eliminating the need for ramps, platforms and stairs typically required with prefabricated structures that have integrated floors. With fully integrated MEP, the floorlessPOD is an ideal solution when the cleanroom cannot be structurally supported by the host facility.

Following project close out, the G-CON Service Team will ensure that your PODs continue to function as intended. Service offerings include preventative maintenance plans, spare parts, NEBB certified TAB services (testing, adjusting, and balancing), and expedited support options. Additionally, the Service Team handles all warranty requests and manages data from these activities to drive continuous improvement in our products’ performance across all aspects.

Learn about the customization of cleanroom doors to meet specific operational and design requirements. This paper highlights GCS's ability to tailor door solutions, ensuring seamless integration with existing cleanroom infrastructure while maintaining efficiency, sterility, and compliance with industry standards. With a commitment to quality, compliance, and efficiency, GCS delivers door solutions designed to enhance cleanroom performance and meet the stringent demands of controlled environments.

The right cell line development technology can address production challenges associated with expression and scalability of complex biologics.

GCS manufactures cleanroom components designed for critical environments, prioritizing the use of sustainable and responsible materials, without compromising the quality and performance of our products. GCS, with its broad range of highly innovative products for the cleanroom infrastructure market, provides clients access to premium cleanroom materials such as modular wall and ceiling panels, cleanroom and specialty doors and other unique components.

G-CON’s floorlessPOD is a free-standing structure that provides direct integration with the host facility floor, eliminating the need for ramps, platforms and stairs typically required with prefabricated structures that have integrated floors. With fully integrated MEP, the floorlessPOD is an ideal solution when the cleanroom cannot be structurally supported by the host facility.

The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.

Combining on- and off-site construction approaches reduces project risk while offering benefits to schedule, flexibility, and cost of ownership for new cleanroom construction.

Plasmid DNA (pDNA) is a critical starting material used to manufacture viral and nonviral cell and gene therapies (CGT).

Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.

Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.

There are several advantages to using a novel capillary electrophoresis-mass spectrometry (CE-MS) device. The REBEL from 908 Devices offers a streamlined and efficient alternative to traditional liquid chromatography-mass spectrometry (LC-MS) for bioprocess monitoring. This paper highlights how this new technology can simplify media analysis, reduce method development time, and improve real-time data collection for biotherapeutic production.

Get a better understanding of dissolved oxygen (DO) measurement in Hamilton's comprehensive O2 Measurement Guide. This 72-page booklet is intended for anyone with an interest in DO sensor technology or anyone who needs to implement DO sensors in controlled environments such as laboratories and industrial plants.

Get a better understanding of pH measurement in Hamilton’s comprehensive pH Measurement Guide. This 68-page booklet is intended for anyone with an interest in pH sensor technology or anyone who needs to implement pH sensors in controlled environments such as laboratories and industrial plants.

The eBook features must-see examples of real applications using Hamilton viable cell density monitoring (Incyte) and total cell density monitoring (Dencytee) and demonstrates how to leverage Viable Cell Density Monitoring in your processes.

Precision fermentation, a sustainable method for producing alternative food ingredients, faces significant technical challenges. This white paper explores the critical role of Process Analytical Technology (PAT) in overcoming these hurdles and ensuring product quality through a Quality-by-Design (QbD) approach. Through a comprehensive review of literature and case studies, key technical challenges are identified to demonstrate how PAT can enhance scalability and sustainability. This paper also highlights the transformative potential of PAT in advancing precision fermentation as a reliable solution for addressing nutritional deficiencies and fostering a circular economy.

Illuminating industry trends, challenges and sentiments

BioPharm International sat down with Jean-François Vincent-Rocan, Director of Complex Chemistry Process Development at BIOVECTRA, to discuss antibody-drug conjugate (ADC) manufacturing. Due to their complex manufacture and supply chain management, JF emphasizes the need for a company that greatly understands the challenges and offers solutions that maintain quality and reliability. He also mentions what advancements are to come in this field and how best to stay ahead of a rapidly growing treatment option.

Application Notebook highlighting Liquid Chromatography techniques commonly used for monitoring Critical Quality Attributes (CQAs) in Bioprocessing Applications

Catalent has developed a cutting-edge bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to measure transcription activity in cells treated with ligands or transgenic vectors. This reliable and reproducible assay is a valuable tool for evaluating the relative potency of various test substances. Enhance your research with Catalent’s robust cell-based potency assays.

Transcriptional activity within a cell can be used to evaluate cell response to a ligand or promoter activity within a transgene or plasmid within a cell. Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors. The assay utilizes two fluorescent dyes with minimally overlapping emission spectra that allow real-time monitoring of the gene expression of both target and normalizer genes. The assay does not require purification of the mRNA produced by the cells once lysis has occurred. Normalizing the qPCR cycle thresholds (CT) of the target transcript to the reference transcript allows response curve to be generated and compared to a reference standard. The generation of a four-parameter fit curve analysis from raw qPCR cycle threshold data allows for comparison of relative potency and assessment of suitability based on curve parallelism. The assay platform has been used by Catalent to qualify a repeatable, accurate, linear, and specific bioassay for assessing relative potency.

The manufacture of protein-based drugs is complex and relies on using biological host systems. This can result in small changes in protein structure during production and formation of protein variants that can have a large impact on functionality. This heterogeneity — variations in the protein size, charge or structure — can significantly impact the safety and activity of the final biotherapeutic or biosimilar therapy, potentially hindering their beneficial effect. It is vital that charged variant profiles of biologics are adequately characterized, as many post-translational modifications (PTMs) may alter the charge of the molecule, in turn impacting its stability, pharmacokinetics and pharmacodynamics. In this article, Catalent explores protein variants, focusing on charged variants, by outlining their impact on protein-based drugs, and explain how specific characterization techniques can be used to determine product safety and efficacy.